Insitro

company

About

Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.

  • 101 - 250

Details

Last Funding Type
Series A
Last Funding Money Raised
$100M
Industries
Biotechnology,Life Science,Machine Learning,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2018
Number Of Employee
101 - 250
Operating Status
Active

Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.

The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

In 2018, Daphne Koller established Insitro in South San Francisco, California..

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$743M
Insitro has raised a total of $743M in funding over 2 rounds. Their latest funding was raised on Mar 15, 2021 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 15, 2021 Series C $400M 1 Detail
May 26, 2020 Series B $143M 1 Detail
Apr 16, 2019 Series A $100M 1 Detail
May 2, 2018 Series A $100M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Insitro is funded by 2 investors. ARCH Venture Partners and Verily are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series C
Verily Series A